MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
GNFT - Genfit
$4.17
-0.03(-0.71%)8:00:00 PM 5/12/2021
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Stock news

    05/12/2021GNFT
    GENFIT: Reports First Quarter 2021 Financial Information

    (Unaudited financial information under IFRS) Cash and cash equivalents totaled €109 million as of March 31, 2021 Lille, France; Cambridge, MA; May 12, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its cash position as of March 31, 2021 and revenues for the first three months of 2021.Cash position As of March 31, 2021, the Company’s cash and cash equivalents amounted...

    05/11/2021GNFT
    GENFIT Provides Pipeline Update and Launch of New Clinical Programs

    R&D effort refocused on two therapeutic areas with significant unmet medical needs: ACLF and cholestatic diseasesGENFIT well positioned to leverage its experience from discovery to late development stages in these severe liver diseasesThese two new franchises will focus on developing NTZ, elafibranor and GFT1575 drug-candidatesThree new clinical trials to be launched in 4Q21 in ACLF, PSC and PBC, with data expected in 2022 Lille, France; Cambridge, MA; May 11, 2021 - GENFIT (Nasdaq and Euronext:...

    05/10/2021GNFT
    GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents

    Lille, France; Cambridge, MA; May 10, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced that it published in the May 10, 2021 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 15, 2021, at 2:30pm, at the Company’s headquarters, located at ...

    05/3/2021GNFT
    GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH

    Test Available Exclusively through Labcorp in the U.S. and Canada Lille, France; Cambridge, MA; May 3, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the launch of NASHnext®, a novel, noninvasive diagnostic test for nonalcoholic steatohepatitis (NASH). The test is offered exclusively in the U.S. and Canada through Labcorp, a leading global life sciences company. NASH...

    04/23/2021GNFT
    GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021

    Lille, France; Cambridge, MA; April 23, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the filing of its 2020 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC) and that its annual shareholders meeting will take pl...

    04/22/2021GNFT
    GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee

    Lille, France; Cambridge, MA; April 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that Thomas Baetz has been appointed as Chief Financial Officer. Thomas Baetz joins the Executive Committee, along with Stefanie Magner, Chief Compliance Officer. Thomas Baetz has 18 years of extensive global experience in corporate finance and investment, acquired in both start-up...

    04/1/2021GNFT
    GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update

    GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update Cash position of €171 million as of December 31, 2020, excluding the €47.5 million partial buyback of the OCEANEs completed in January 2021, that cancelled €85.7 million nominal amount of convertible debtAdditional €30.6 million nominal amount of convertible debt cancelled following conversion by bondholders, bringing outstanding nominal debt down to €63.6 million as of March 12, 2021 (i.e. <1/3 of initial debt value)3...

    03/4/2021GNFT
    GENFIT appoints Jean-François Tiné to the Board of Directors

    Lille, France; Cambridge, MA; March 04, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the appointment of Jean-François Tiné as an independent board member. GENFIT’s Board of Directors has appointed Jean-François Tiné to replace Philippe Moons who resigned from his position as member of the Board. Jean-François Tiné will also join the Strategy and Alliances Committee...

    03/1/2021GNFT
    Indus Announces Launch of Public Offering of 1,750,000 Shares of Common Stock

    NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) today announced that it has commenced an offering of 1,750,000 shares of common stock. The Company also plans to grant the underwriters a 30-day option to purchase up to 262,500 additional shares of common stock. INDUS intends to use the net proceeds from the offering to finance its development pipeline and acquisitions and for other corporate purposes. Morgan Stanley and Citigroup are...